Eyebuystox, my sense is that PPHM management already has the interim results in hand from the various studies at their varied levels of maturity to "knock the socks off" any Pharma that will be trying to defend their standard of care treatment that can be reinforced through cotreatment with Bavi or displaced by Bavi through cotreatment with a competitors product. The interim data is not press release worthy, but should be strong directionally. What PPHM needed was to reconcile any residual issues with the 2nd line NSCLC trial coding error(s) and see the first line trial and/or pancreatic trial mature enough to demonstrate those additional months of MOS.
So what presentation event, external meeting, employee incentive distribution or expert buy in validation is PPHM waiting for now that they have announced the salvaging of the 2nd line NSCLC trial? It seems to me that PPHM is holding some cards back while waiting for something to synchronize for their big picture Bavi development planning. Is it just that they are waiting for a Pharma to bless the announcement of their partnering existence?
Best wishes and IMO.
KT
Market Data 
Markets 
AI
